The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker compound of formula (I) wherein R1 and R2 are independently hydrogen, C1-6alkyl or C3-6cycloalkylC1-6alkyl； or R1 and R2, together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring； R3 is C1-6alkyl, C1-6haloalkyl, C1-3alkoxyC1-3alkyl or C1-3haloalkoxyC1-3alkyl； or R1 and R3, together with the interconnecting atoms, form a saturated or unsaturated 4- to 6-membered ring； X is carbon or nitrogen； n is 0, 1 or 2, wherein when present each R4 is independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy； q is 1 or 2； either R5 or R6 is -O-R7 or -OCH2R7, wherein the other R5 or R6 is hydrogen or R4； and wherein R7 is either a phenyl ring or a 5- or 6-membered aromatic heterocyclic ring (independently containing one or more nitrogen, sulphur or oxygen atoms) wherein either the phenyl ring or the heterocyclic ring is optionally substituted by one or more groups independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy； or a pharmaceutically acceptable salt or solvate thereof； as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy and mood disorders.
